Omnix Medical

Omnix Medical Overview

Omnix Medical is a clinical-stage biopharmaceutical company developing next-generation of anti-infective drugs. We are determined to provide a safer, more efficient alternative to win the battle against AMR by offering therapies that are, by design, resilient against resistance development. Omnix Medical was founded in 2015 to address the urgent unmet need for new life-saving anti-infective drugs. Omnix´ proprietary technology eliminates bacteria by mimicking the innate immune system of insects which uses unique molecules to kill resistant bacterial strains efficiently and selectively without toxic effects. Omnix´ technology prevents the development of new resistances and is thus well positioned to become a first-line-treatment in a highly unmet need. The Company’s lead compound, OMN6, is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 is being developed for the treatment of life-threatening hospital-acquired infections (HIA) caused by the Gram-negative bacteria Acinetobacter baumannii, and has shown significantly higher potency than currently available treatments. Recently, Omnix has initiated a Phase 2 Proof-of-Concept trial of the company´s novel anti-infective OMN6 in HABP/VABP patients under IND approval from the FDA. Omnix team is hard at work with several active sights for the Phase 2 clinical trial as well as advancing our pipeline molecules and our mission to introduce new life-saving anti-infectives.

Cumulative Funding Raised Over Time ($)

Latest News

Oct 15, 2025 · www.calcalistech.com

growth-positive

Omnix Medical raises $25 million Series C to tackle drug-resistant infections | CTech

Omnix Medical, an Israeli biopharmaceutical company, has secured $25 million in a Series C funding round led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund. The funding will support the completion of Phase II clinical trials for its lead compound, OMN6, aimed at treating antibiotic-resistant infections. The company plans to use the funds for regulatory preparations, manufacturing scale-up, and further development of its antimicrobial peptide pipeline. OMN6 has received Fast-Track and Qualified Infectious Disease Product status from the FDA, highlighting its potential in combating drug-resistant bacteria.

InvestmentProduct Stage

Oct 15, 2025 · www.calcalistech.com

growth-positive

Israeli biotech secures funding to complete Phase II trials for its novel antimicrobial peptide therapy.

Omnix Medical, an Israeli biopharmaceutical company, has secured $25 million in a Series C funding round led by Harel Insurance & Finance and the European Innovation Council Fund. The funding will support the completion of Phase II trials for their lead compound, OMN6, which targets antibiotic-resistant infections. The compound has received Fast-Track and QIDP status from the FDA. The investment will also aid in regulatory preparations, manufacturing scale-up, and the development of other antimicrobial peptides. Omnix has raised a total of $43 million since its inception in 2015.

InvestmentProduct Stage

Jan 26, 2021 · www.calcalistech.com

growth-positive

Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria

Omnix Medical, an Israeli biopharmaceutical company, has been awarded €10.8 million in EU funding to develop next-generation anti-infectives for the treatment of antibiotic-resistant infections. The funding is part of the EUs Horizon 2020 program for research and innovation. Omnix Medicals novel agents are designed as an alternative to classical antibiotics, targeting bacterial membranes to destroy bacteria regardless of existing resistances. The funding will allow the company to advance its lead compound OMN6 through clinical proof-of-concept studies. Omnix Medical has raised a total of €20 million to date from investors including Tal Capital, Entrée Capital, the CBG Group, Xenia Ventures, and VLX Ventures. Dr. Antonius Schuh has been appointed as Chairman of the Board of Directors.

Investment

Nov 3, 2020 · www.calcalistech.com

growth-positive

Omnix Medical completes $8.5 million round to develop next-generation antibiotics for treatment of life-threatening infections

Omnix Medical, an Israeli startup developing novel antibiotic agents, has completed an $8.5 million funding round led by Tal Capital and Entrée Capital. The funding will allow the company to begin clinical trials with humans after successfully completing testing in animals. Omnix Medical plans to test its flagship solution, OMN6, which represents a new antibiotic class with a rapid-bactericidal effect. The company aims to bring groundbreaking and life-saving technology to the market. Omnix Medical was founded by Dr. Moshik Cohen-Kutner, Dr. Niv Bachnoff, and Rom Lakritz, who developed their solution based on the immune systems of insects. The company has raised a total of $10 million since its founding in 2015.

Investment

Jan 31, 2019 · www.jpost.com

growth-negative

https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Despite-one-companys-claims-many-experts-are-uncertain-579362

Israeli company Accelerated Evolution Biotechnologies Ltd. (AEBi) has faced criticism after claiming to have discovered a cure for cancer. The claim was made by AEBis chairman of the board, Dan Aridor, and its CEO, Dr. Ilan Morad, who said their treatment, MuTaTo, is essentially a cancer antibiotic. However, experts have disputed the claim, stating that the research is far from proven. Despite the criticism, AEBi maintains that the treatment will be available for testing on humans within a year.

CustomersInvestment

Funding

Team Members

5

Employees: 11-50

Web & Social Links

Locations

Givat Ram, Jerusalem, Israel

Photos & Videos

2 item(s)

Omnix Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info